RxDoctor Payments Data

Deborah Eisen, MD

Pulmonary Disease · Toms River, NJNPI 1265428874

Payments from drug & device makers

$2,465in general payments, 2019–2025

Across 181 payments — averaging $13.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$888
  • GSK$601
  • Boehringer Ingelheim$407
  • Mylan Specialty L.p.$93
  • Sanofi$63
  • Philips North America LLC$49
  • plus $363 from 15 others

What the payments were for

  • Food & beverage$2,39397%
  • Education$713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,465 in reported general payments places this provider in the 50th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$357,886
Medicare patients
756
Services billed
4,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter233$251,849
OfevNintedanib Esylate19$213,551
Breztri AerosphereBudesonide/Glycopyr/Formoterol220$213,148
Breo ElliptaFluticasone/Vilanterol278$172,197
Dupixent PenDupilumab18$66,974
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$61,212
AdcircaTadalafil13$53,126
Spiriva RespimatTiotropium Bromide41$42,228
NucalaMepolizumab11$40,610
Albuterol Sulfate HfaAlbuterol Sulfate754$34,361
Advair HfaFluticasone Propion/Salmeterol71$33,539
SymbicortBudesonide/Formoterol Fumarate115$33,002
Bevespi AerosphereGlycopyrrolate/Formoterol Fum57$30,828
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$27,934
Fluticasone-SalmeterolFluticasone Propion/Salmeterol91$24,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta$601$533,336618 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$407$283,71390 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$888$276,978392 claims
United Therapeutics CorporationAdcirca$21$53,12613 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Proair Respiclick$37$11,37637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →